CA2086325A1 - Ligand pour le recepteur cd28 sur les cellules b et methodes - Google Patents

Ligand pour le recepteur cd28 sur les cellules b et methodes

Info

Publication number
CA2086325A1
CA2086325A1 CA002086325A CA2086325A CA2086325A1 CA 2086325 A1 CA2086325 A1 CA 2086325A1 CA 002086325 A CA002086325 A CA 002086325A CA 2086325 A CA2086325 A CA 2086325A CA 2086325 A1 CA2086325 A1 CA 2086325A1
Authority
CA
Canada
Prior art keywords
amino acid
receptor
acid sequence
antigen
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002086325A
Other languages
English (en)
Other versions
CA2086325C (fr
Inventor
Peter S. Linsley
Jeffrey A. Ledbetter
Nitin K. Damle
William Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2086325A1 publication Critical patent/CA2086325A1/fr
Application granted granted Critical
Publication of CA2086325C publication Critical patent/CA2086325C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Dans cette invention, on identifie l'antigène B7 comme ligand réactif pour le récepteur CD28 sur les cellules T. On y décrit des fragments et des dérivés de l'antigène B7 et du récepteur CD28, y compris des protéines hybrides ayant des séquences d'acides aminés correspondant aux domaines extracellulaires de B7 ou de CD28 jointes à des séquences d'acides aminés encodant des portions de l'immunoglobuline humaine C.gamma.1. On y fournit des méthodes pour utiliser l'antigène B7, ses fragments et ses dérivés, et le récepteur CD28, ses fragments et ses dérivés, ainsi que des anticorps et d'autres molécules réactifs avec l'antigène B7 et/ou le récepteur CD28, afin de réguler les réponses positives des cellules T au CD28 et des réponses immunitaires assistées par les cellules T. L'invention comprend aussi une méthode pour une épreuve de détection de ligands réactifs avec les récepteurs cellulaires favorisant l'adhésion intercellulaire.
CA2086325A 1990-07-02 1991-07-01 Ligand pour le recepteur cd28 sur les cellules b et methodes Expired - Lifetime CA2086325C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54798090A 1990-07-02 1990-07-02
US547,980 1990-07-02
US72210191A 1991-06-27 1991-06-27
US722,101 1991-06-27
PCT/US1991/004682 WO1992000092A1 (fr) 1990-07-02 1991-07-01 Ligand pour recepteur a cd28 sur des lymphocytes b et procedes

Publications (2)

Publication Number Publication Date
CA2086325A1 true CA2086325A1 (fr) 1992-01-03
CA2086325C CA2086325C (fr) 2010-10-05

Family

ID=27068718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2086325A Expired - Lifetime CA2086325C (fr) 1990-07-02 1991-07-01 Ligand pour le recepteur cd28 sur les cellules b et methodes

Country Status (4)

Country Link
EP (1) EP0537293A4 (fr)
JP (2) JPH06508501A (fr)
CA (1) CA2086325C (fr)
WO (1) WO1992000092A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1992015671A1 (fr) * 1991-03-08 1992-09-17 Cytomed, Inc. Proteines cd28 solubles et procedes de traitement au moyen desdites proteines
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0637963B1 (fr) * 1992-04-07 2004-08-04 The Regents of the University of Michigan Immunoregulation recourant a la voie d'acces du cd28
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0945465B1 (fr) * 1992-07-09 2006-09-13 Novartis Vaccines and Diagnostics, Inc. Anticorps monoclonaux antagonistes contre la molécule humaine CD40
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
MX9306147A (es) * 1992-10-02 1994-06-30 Bristol Myers Squibb Co Composicion farmaceutica para inhibir el crecimiento de celulas tumorales.
AU6586494A (en) * 1993-04-14 1994-11-08 United States Of America As Represented By The Secretary Of The Navy, The Transgenic animal model for autoimmune diseases
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
DE69434342T2 (de) * 1993-06-04 2006-03-16 The United States Of America Represented By The Secretary Of The Navy Verfahren zur selektiven Stimulierung der T-Zellproliferation.
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
JPH0779793A (ja) * 1993-09-14 1995-03-28 Sumitomo Electric Ind Ltd Ｂ７０分子に対するモノクローナル抗体
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
EP0749323B1 (fr) 1994-03-08 2000-11-29 Dana-Farber Cancer Institute Procedes de modulation de l'anergie des cellules t
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
CA2204183A1 (fr) * 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Recepteurs chimeres servant a produire des lymphocites t cytotoxique th, activables selectivement independants des cellules auxiliaires
ATE384127T1 (de) 1994-12-02 2008-02-15 Schering Corp Kostimulatorisches t-zell-oberflächen-antigen slam
US5576423A (en) * 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
EP0892643B2 (fr) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
GB9607711D0 (en) * 1996-04-13 1996-06-19 Univ Sheffield T-cell dependent vaccine
CA2194814A1 (fr) * 1997-01-10 1998-07-10 Terry L. Delovitch Stimulation des cellules t protectrices pour prevenir les maladies auto-immunes
CN1224712C (zh) 1997-06-04 2005-10-26 牛津生物医学（英国）有限公司 载体
US7279168B2 (en) 1998-05-01 2007-10-09 Texas A & M University System Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
US7078512B2 (en) 1998-05-01 2006-07-18 Schering-Plough Animal Health Corporation Nucleic acid encoding feline CD86
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
WO2001039722A2 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
EP1717251B1 (fr) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Anticorps humains anti-CD40 pour le traitement des tumeurs malignes des lymphocytes B
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP3428191A1 (fr) 2004-10-06 2019-01-16 Mayo Foundation for Medical Education and Research B7-h1 et pd-1 dans le traitement du carcinome des cellules rénales
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
AU2008293885A1 (en) 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2860460A1 (fr) * 2012-01-16 2013-07-25 Atox Bio Ltd. Utilisation de peptides p2ta synthetiques dans le traitement d'infectionbacterienne continue et inflammation associee
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3470081A1 (fr) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (fr) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
ZA91463B (en) * 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
WO1992015671A1 (fr) * 1991-03-08 1992-09-17 Cytomed, Inc. Proteines cd28 solubles et procedes de traitement au moyen desdites proteines

Also Published As

Publication number Publication date
WO1992000092A1 (fr) 1992-01-09
EP0537293A4 (en) 1993-09-08
JP2002186486A (ja) 2002-07-02
JPH06508501A (ja) 1994-09-29
CA2086325C (fr) 2010-10-05
EP0537293A1 (fr) 1993-04-21

Similar Documents

Publication Publication Date Title
CA2086325A1 (fr) Ligand pour le recepteur cd28 sur les cellules b et methodes
Wang et al. VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
Beyers et al. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5.
Brischwein et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
AU2023200608A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
CA2146895A1 (fr) Proteines de fusion hybrides ctla4/cd28ig
Jeong et al. Novel anti-4-1BB× PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
Richards et al. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
CN111315405A (zh) 双特异性融合多肽及其使用方法
CN111423512B (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
JP7362614B2 (ja) 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質
Hanson et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
US20230235011A1 (en) Fc-cd80 fusion protein and conjugates thereof and their uses
AU2017206618A1 (en) Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
US20170158774A1 (en) Anti-la antibodies and their use for immunotargeting
Semmrich et al. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’tumors
CN114786701A (zh) 用于治疗癌症的包括包含il-2蛋白和cd80蛋白的融合蛋白和免疫检查点抑制剂的药物组合物
Yi et al. Human and mouse CD137 have predominantly different binding CRDs to their respective ligands
CA2461631A1 (fr) Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques
AU734853B2 (en) Methods of prolonged suppression of humoral immunity
Passariello et al. Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo
Guelen et al. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy
Fellermeier-Kopf et al. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans
US20240084011A1 (en) Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
Liu et al. Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry